Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
A legfontosabb adatok
- Ki végzi
- New York Medical College
- Hol
- Milwaukee és Valhalla (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 138 fő, tervezett
- Kezdés
- 2026. szept. 1.
- Várható befejezés
- 2032. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Standard of Care Antiviral medications
- Viral CTLs
- A regiszteradat frissítve
- 2026. szeptember 11.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children, teens and young adults after a donor stem cell transplant. They must have an adenovirus (ADV) or cytomegalovirus (CMV) infection that has not gone away with antiviral medicine.
- Életkor
- 0.01 to 30.00 years (1 day to 30 years)
- Nem
- All sexes can join.
- A betegség stádiuma
- ADV or CMV virus in the blood after a donor stem cell transplant. The virus level (> 1000 copies) keeps rising or stays after 7 days of antiviral therapy, or the person cannot tolerate the antiviral drugs, or the virus is resistant to them. Performance status must be >30% (Lansky under 16 years, Karnofsky over 16 years).
- Korábbi kezelés
- At least 7 days of antiviral therapy, or side effects from cidofovir (ADV), or from ganciclovir, foscarnet or cidofovir (CMV). No donor lymphocyte infusion (DLI) within 4 weeks before the cell infusion.
- Biomarker vagy leletérték
- ADV or CMV RT-PCR DNA > 1000 copies, or known resistance to cidofovir (ADV) or to ganciclovir and/or foscarnet (CMV). A family donor sharing > 3 HLA tissue markers whose T-cells react to the ADV or CMV test peptides.
A részvétel fő kizáró okai
- Acute graft-versus-host disease (GVHD) > grade 2, or moderate or extensive chronic GVHD
- Taking steroids above 0.5 mg/kg prednisone equivalent at the time of the cell infusion
- Known AIDS or uncontrolled HIV infection
- Brain inflammation (encephalitis) and/or eye retinitis
- Known allergy to iron dextran
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Egyéb feltételek
- Patient Eligibility Cohort 1 (ADV) -Patients with ADV viremia (Cohort 1) post AlloHSCT with one or more of the following: Increasing or persistent ADV RT-PCR DNA (> 1000 ADV PCR copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-viral therapies including one or more of the following: > grade 2 renal insufficiency secondary to cidofovir and/or other > grade 2 toxicities secondary to cidofovir AND/OR Known resistance to cidofovir
- Patient Eligibility (Cohort 2) (CMV)
- -Patients with CMV viremia with one or more of the following: Increasing or persistent CMV RT-PCR DNA (>1000 copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-CMV antibiotic therapies: ANC < 500/mm3 secondary to ganciclovir AND/OR > grade 2 renal toxicity secondary to either foscarnet or cidofovir AND/OR Known resistance to ganciclovir and/or foscarnet
- Consent: written informed consent given (by patient or legal representative) prior to any study related procedures
- Performance Status >30% (Lansky < 16 yrs and Karnofsky > 16 years (BOTH COHORTS)
- Age: 0.01 to 30.00 years (BOTH COHORTS)
- Females of childbearing potential with a negative urine pregnancy test at study entry only (BOTH COHORTS)
- Family related donor (> 3 HLA match) that screens positive for ADV5 MACS Peptivator (Cohort 1) or PP65CMV MACS Peptivator (Cohort 2); Donor Eligibility
- Related donor available with a T-cell response to the ADV MACS PepTivators (Cohort 1) or CMV MACS PepTivator (Cohort 2). As defined in Appendix II, B, 8.2, the donor is considered suitable if the percentage of IFN+ T-cells is >0.01% after stimulation with ADV PepTivators (Cohort 1) or CMV PepTivators (Cohort 2)
- Third-party related allogeneic donor: If original donor is not available or does not have a T-cell response to ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2), third party allogeneic donor (family donor > 3 HLA A, B, DR match to recipient) with a T-cell response at least to the ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2) AND
- Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1) AND
- Obtained informed consents by donor or donor legally authorized representative prior to donor collection; Patient Exclusion Criteria (Both Cohorts)
- Patient with acute GVHD > grade 2 or moderate or extensive chronic GVHD at the time of CTL infusion
- Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of CTL infusion
- Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion
- Patient with poor performance status determined by Karnofksy (patients > 16 yrs) or Lansky (patients < 16 years) score < 30%
- Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory ADV or CMV infections
- Any known medical condition which cold compromise participation in the study according to investigators assessment
- Known AIDS or uncontrolled HIV infection
- Known hypersensitivity to iron dextran
- Encephalitis and/or retinitis
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Medical College of WisconsinMilwaukee, Egyesült ÁllamokContact: Julie An Talano, MDToborzás még nem indult
- New York Medical CollegeValhalla, Egyesült ÁllamokContact: Mitchell S Cairo, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
A vizsgálat 2 csoportja
- Standard of Care MedicationMár használt kezelés, összehasonlításként
Patients will receive standard of care antiviral therapy for CMV or ADV at the discretion of the physician.
Kezelés: Standard of Care Antiviral medications
- Standard of Care Medication plus Cytotoxic T-Lymphocytes (CTLs)A vizsgált kezelés
Patients will be randomized to receiving standard of care antiviral therapy plus family matched donor derived CTLs.
Kezelés: Standard of Care Antiviral medications és Viral CTLs
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 11.